These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 15793108)

  • 21. Efficacy of doripenem in the treatment of Pseudomonas aeruginosa experimental pneumonia versus imipenem and meropenem.
    Bretonnière C; Jacqueline C; Caillon J; Guitton C; Le Mabecque V; Miégeville AF; Villers D; Potel G; Boutoille D
    J Antimicrob Chemother; 2010 Nov; 65(11):2423-7. PubMed ID: 20858688
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics of imipenem in healthy volunteers following administration by 2 h or 0.5 h infusion.
    Jaruratanasirikul S; Raungsri N; Punyo J; Sriwiriyajan S
    J Antimicrob Chemother; 2005 Dec; 56(6):1163-5. PubMed ID: 16234333
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative pharmacokinetics and pharmacodynamics of doripenem and meropenem in obese patients.
    Kays MB; Fleming MR; Cheatham SC; Chung EK; Juenke JM
    Ann Pharmacother; 2014 Feb; 48(2):178-86. PubMed ID: 24259653
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Steady-state pharmacokinetics and pharmacodynamics of cefepime administered by prolonged infusion in hospitalised patients.
    Cheatham SC; Shea KM; Healy DP; Humphrey ML; Fleming MR; Wack MF; Smith DW; Sowinski KM; Kays MB
    Int J Antimicrob Agents; 2011 Jan; 37(1):46-50. PubMed ID: 21074370
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Extended versus bolus infusion of meropenem and piperacillin: a pharmacokinetic analysis.
    De Waele J; Carlier M; Hoste E; Depuydt P; Decruyenaere J; Wallis SC; Lipman J; Roberts JA
    Minerva Anestesiol; 2014 Dec; 80(12):1302-9. PubMed ID: 24762706
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of Short Versus Prolonged Infusion of Standard Dose of Meropenem Against Carbapenemase-Producing Klebsiella pneumoniae Isolates in Different Patient Groups: A Pharmacokinetic-Pharmacodynamic Approach.
    Vourli S; Tsala M; Kotsakis S; Daikos GL; Tzouvelekis L; Miriagou V; Zerva L; Meletiadis J
    J Pharm Sci; 2016 Apr; 105(4):1513-8. PubMed ID: 27019965
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intrapulmonary pharmacokinetics and pharmacodynamics of meropenem.
    Conte JE; Golden JA; Kelley MG; Zurlinden E
    Int J Antimicrob Agents; 2005 Dec; 26(6):449-56. PubMed ID: 16280244
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacodynamic evaluation of extending the administration time of meropenem using a Monte Carlo simulation.
    Lomaestro BM; Drusano GL
    Antimicrob Agents Chemother; 2005 Jan; 49(1):461-3. PubMed ID: 15616337
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of 30-min and 3-h infusion regimens for imipenem/cilastatin and for meropenem evaluated by Monte Carlo simulation.
    Lee LS; Kinzig-Schippers M; Nafziger AN; Ma L; Sörgel F; Jones RN; Drusano GL; Bertino JS
    Diagn Microbiol Infect Dis; 2010 Nov; 68(3):251-8. PubMed ID: 20851549
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antibacterial activity of achievable epithelial lining fluid exposures of Amikacin Inhale with or without meropenem.
    So W; Crandon JL; Hamada Y; Nicolau DP
    J Antimicrob Chemother; 2016 Feb; 71(2):428-37. PubMed ID: 26559690
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics of imipenem in critically ill patients during empirical treatment of nosocomial pneumonia: a comparison of 0.5-h and 3-h infusions.
    Lipš M; Siller M; Strojil J; Urbánek K; Balík M; Suchánková H
    Int J Antimicrob Agents; 2014 Oct; 44(4):358-62. PubMed ID: 25216543
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacodynamic-based clinical pathway for empiric antibiotic choice in patients with ventilator-associated pneumonia.
    Nicasio AM; Eagye KJ; Nicolau DP; Shore E; Palter M; Pepe J; Kuti JL
    J Crit Care; 2010 Mar; 25(1):69-77. PubMed ID: 19427167
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of meropenem in combination with tobramycin in a murine model of Pseudomonas aeruginosa pneumonia.
    Louie A; Liu W; Fikes S; Brown D; Drusano GL
    Antimicrob Agents Chemother; 2013 Jun; 57(6):2788-92. PubMed ID: 23571540
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacodynamics of imipenem in critically ill patients with ventilator-associated pneumonia.
    Jaruratanasirikul S; Aeinlang N; Jullangkoon M; Wongpoowarak W
    J Med Assoc Thai; 2013 May; 96(5):551-7. PubMed ID: 23745309
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical efficacy of continuous infusion of piperacillin compared with intermittent dosing in septic critically ill patients.
    Rafati MR; Rouini MR; Mojtahedzadeh M; Najafi A; Tavakoli H; Gholami K; Fazeli MR
    Int J Antimicrob Agents; 2006 Aug; 28(2):122-7. PubMed ID: 16815689
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics and pharmacodynamics of meropenem in febrile neutropenic patients with bacteremia.
    Ariano RE; Nyhlén A; Donnelly JP; Sitar DS; Harding GK; Zelenitsky SA
    Ann Pharmacother; 2005 Jan; 39(1):32-8. PubMed ID: 15598967
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Steady-state pharmacokinetics and pharmacodynamics of meropenem in morbidly obese patients hospitalized in an intensive care unit.
    Cheatham SC; Fleming MR; Healy DP; Chung EK; Shea KM; Humphrey ML; Kays MB
    J Clin Pharmacol; 2014 Mar; 54(3):324-30. PubMed ID: 24122855
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Population pharmacokinetics of meropenem administered as a prolonged infusion in children with cystic fibrosis.
    Pettit RS; Neu N; Cies JJ; Lapin C; Muhlebach MS; Novak KJ; Nguyen ST; Saiman L; Nicolau DP; Kuti JL
    J Antimicrob Chemother; 2016 Jan; 71(1):189-95. PubMed ID: 26416780
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Might real-time pharmacokinetic/pharmacodynamic optimisation of high-dose continuous-infusion meropenem improve clinical cure in infections caused by KPC-producing Klebsiella pneumoniae?
    Pea F; Della Siega P; Cojutti P; Sartor A; Crapis M; Scarparo C; Bassetti M
    Int J Antimicrob Agents; 2017 Feb; 49(2):255-258. PubMed ID: 28012683
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dosing regimen of meropenem for adults with severe burns: a population pharmacokinetic study with Monte Carlo simulations.
    Ramon-Lopez A; Allen JM; Thomson AH; Dheansa BS; James SE; Hanlon GW; Stewart B; Davies JG
    J Antimicrob Chemother; 2015 Mar; 70(3):882-90. PubMed ID: 25362574
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.